---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-065087"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:14:50.943198+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta reports Q4 net loss $28.1M; initiates EDP-323 Phase 2a RSV study

## Summary
- Q4 revenue $18.9M (down from $20.3M YoY); FY revenue $79.2M (down from $86.2M).
- Net loss $28.1M ($1.33/diluted share) vs $26.3M ($1.27) in Q4 2022; FY loss $133.8M ($6.38) vs $121.8M ($5.91).
- Cash and marketable securities $370M; expects to fund operations through fiscal 2027.
- FY2024 guidance: R&D $100-120M (down from $163.5M actual), G&A $45-50M (down from $52M).
- Initiated Phase 2a challenge study for RSV candidate EDP-323; data expected Q3 2024. Advancing EDP-938 Phase 2 trials.

## SEC filing metadata
- accession: 0000950170-23-065087
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/0000950170-23-065087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/enta-20231120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-065087
- JSON: https://secwatch.observer/filing/0000950170-23-065087.json
- Plain text: https://secwatch.observer/filing/0000950170-23-065087.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC updated its fiscal fourth quarter and year ended September 30, 2023 guidance (lowered).
  - Period: fiscal fourth quarter and year ended September 30, 2023
  - Guidance: lowered
  - Result: reported results
  source text: On November 20, 2023, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/0000950170-23-065087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.